The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic correlates of response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine tumors.
 
Patrick Lee
No Relationships to Disclose
 
Edik Matthew Blais
Employment - AstraZeneca (I); BridgeBio (I); Emerald Cloud Labs (I); Perthera
Leadership - Perthera
Stock and Other Ownership Interests - Perthera
Patents, Royalties, Other Intellectual Property - Named as an inventor on patents filed by Perthera, Inc. (as an employee)
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; Clinical Congress Consultants; Elsevier; EMD Serono; Exelixis; HalioDx; Janssen Biotech; Natera; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; Clinical Congress Consultants; Elsevier; Exelixis; QED Therapeutics
 
Arsen Osipov
No Relationships to Disclose
 
Natalie Moshayedi
No Relationships to Disclose
 
Shant Thomassian
No Relationships to Disclose
 
Camille Ng
No Relationships to Disclose
 
Jennifer W. Chuy
Other Relationship - Loki Therapeutics
 
Lynn McCormick Matrisian
Other Relationship - Abbvie (Inst); Amgen Foundation (Inst); AstraZeneca (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Covance/LabCorp (Inst); Elevation Oncology (Inst); FibroGen (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Immunovia (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); SERVIER (Inst); Takeda (Inst); Tempus (Inst); TriSalus Life Sciences (Inst); TYME (Inst); ViewRay (Inst)
 
Emanuel Petricoin
Leadership - Ceres Nanosciences; Perthera
Stock and Other Ownership Interests - Ceres Nanosciences; Perthera; Theralink
Consulting or Advisory Role - Ceres Nanosciences; Perthera; Theralink
Research Funding - Abbvie (Inst); Ceres Nanosciences (Inst); G1 Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - NIH Patents Licensing Fee Distribution/Royalty; University assigned patent licensing fee/royalty
Travel, Accommodations, Expenses - Ceres Nanosciences; Perthera
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; Novartis; Pfizer; TriSalus Life Sciences
Research Funding - Ambrx (Inst); Amgen (Inst); Arcus Biosciences (Inst); BioMed Valley Discoveries (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
(OPTIONAL) Uncompensated Relationships - RenovoRx
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera; Valar Labs
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen